focus -WSS

focus

author：focus 2025-09-27 21:27:14 - browse：551

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

WSS

Why Talkspace is targeting Medicare, a tricky market

Change Healthcare cyberattack shows risk of industry consolidation

Pregnant women don't need prenatal multivitamins, study concludes

Cholera vaccine supplies dangerously low, outbreaks surging

STAT Madness 2024: Meet the contenders

Children’s Hospital revives plan for pedestrian bridge

entertainment

focus

Wikipedia

Activists slam private health insurers over coverage restrictions

Medicare drug price negotiation continues, as pharma counteroffers

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Using force crossed my mind when examining a defiant young patient

DIEP, the 'gold standard' of breast reconstruction, is under threat

First over

State Dept. review finds Biden bears some blame for Afghanistan failures

Biden's 'march

Moonlake's readout produced a cash windfall. Risks remain

A new approach to psychiatric drug development

knowledge

Virtual repurposing can help discover new uses for existing drugs

For AI in health care standards, federal regulators join with industry group

Medicare drug price negotiation hearing pits pharma v Biden admin

Are embryos people? Reproductive medicine's future depends on the answer

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Pregnant women don't need prenatal multivitamins, study concludes

focus

explore

focus

hotspot